RT Book, Section
A1 Rios, Adan
A1 Hagemeister, Fredrick B.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
A2 Koller, Charles A.
SR Print(0)
ID 8313801
T1 Chapter 41. The AIDS-Related Cancers
T2 The MD Anderson Manual of Medical Oncology, 2e
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-170106-8
LK accessmedicine.mhmedical.com/content.aspx?aid=8313801
RD 2019/06/15
AB The  relationship  between  malignancies  and  AIDS  began  changing  in  1996  (1,2)  when  the  highly  active  antiretroviral  (HAART)  therapy  regimens  were  introduced  in  the  industrial  nations.  Thanks  to  the  United  Nations  efforts  and  to  general  programs  of  economic  support  and  philanthropy,  HAART  has  also  been  successfully  introduced  into  a  significant  number  of  developing  nations.  Africa,  the  main  epicenter  of  the  pandemic,  has  been  the  exception,  due  to  the  sheer  magnitude  of  the  African  epidemic.  Significant  political  and  social  turmoil  has  hampered  the  efficiency  of  these  efforts  in  Africa  (3).  Prior  to  1996,  epidemiologists  noted  that  specific  malignancies  afflicted  patients  with  AIDS,  and  that  the  risk  of  development  of  a  malignancy  was  directly  proportional  to  the  degree  of  immunodeficiency  of  the  infected  host.  Before  the  development  of  HAART,  patients  with  AIDS  could  be  separated  into  two  groups:  patients  who  would  have  an  opportunistic  infection  as  their  first  manifestation  of  AIDS  (60%)  and  those  who  would  have  a  malignancy  as  the  mode  of  presentation  (40%)  (4).